Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Date:2/24/2009

AMSTERDAM, the Netherlands, February 24 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year of 2008.

    Highlights

    - Extra clinical trial in LPL deficiency causes a delay of the announced
      filing date for lead product GlyberaTM which is now expected H2 2009
    - Positive clinical data on GlyberaTM
    - CEO Ronald Lorijn resigned for personal reasons
    - Start of clinical multicenter Hemophilia B trial in 2009
    - Start development of treatments for Duchenne Muscular Dystrophy and
      Parkinson's disease
    - Scale up of unique and proprietary production platform to fully support
      worldwide commercial supply for current products
    - Independent supervisory board with three new members bringing extensive
      knowledge and experience.
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 34.2 million at December 31, 2008

Results comparison

AMT's operating loss increased to EUR 18.8 million for 2008, from EUR 14.7 million for 2007. The difference is primarily due to the increase of research & development costs to EUR 13.1 million, from EUR 9.8 million in 2007. This increase is particularly related to the development work on the company's lead product, GlyberaTM, increased staffing for this and other programs and an increase in research collaborations. General and administrative costs increased to EUR 5.9 million, from EUR 5.0 million in 2007, primarily as a result of increased employee costs and increased advisor's fees. The net loss for 2008 was EUR 16.9 million, as compared to a net loss of EUR 14.9 million for 2007. As of December 31, 2008, AMT had cash and cash equivalents of EUR 34.2 million, compared to EUR 51.3 million at December 31, 2007. The cash burn for the year amounted to EURO 17.2 million which i
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
4. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
10. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
11. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Dr. Williams says, “Bush has joined the ... the greatest health care system in the world is ... while trying to serve the public. Unfortunately, Bush has ... an enormous system that none of them can first ... series of Open Letters ( http://is.gd/wdU2CM ) provides a ...
(Date:7/21/2014)... Syracuse University,s College of Arts and Sciences has ... of stainless nanoparticles. , Mathew M. Maye, associate ... $360,000 grant from the National Science Foundation (NSF). ... stainless alloy nanostructures, the results of which may ... batteries. , Maye,s approach is novel, ...
(Date:7/21/2014)... Sunset, LA (PRWEB) July 21, 2014 ... poor sleep quality are closely correlated with depression. ... Institutes of Health: "About three quarters of ... present in about 40% of young depressed adults ... in females. The symptoms cause huge distress, have ...
(Date:7/18/2014)... , July 18, 2014 Regeneron Pharmaceuticals, Inc. ... quarter 2014 financial and operating results on Tuesday, August ... Company will host a conference call and simultaneous webcast ... Conference Call InformationTo access this call, dial (888) ... the webcast may be accessed from the ,Events and ...
Breaking Biology Technology:Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3
... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... development and commercial supply agreement with Hospira ... business unit to manufacture clinical-grade Oxycyte(R). Oxycyte ... carrier. Oxycyte will be manufactured at Hospira,s ...
... on the 1918 Spanish Influenza Strain Protected Mice and ... Bird FluROCKVILLE, Md., April 14 ... NVAX ) today reported preclinical study results ... based on the 1918 Spanish influenza strain protected against ...
... - BioMS Medical Corp. (TSX: MS), a leading developer ... that the independent Data Safety Monitoring Board (DSMB) for ... dirucotide in patients with secondary progressive MS has completed ... as per the protocol. , This was the fourth ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 3NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 4NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 5BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2
(Date:7/21/2014)... Mark DeCoster, the James E. Wyche III Endowed ... will present as an invited speaker at the ... Research and Development Center in Singapore. , DeCoster, ... Louisiana Tech,s Institute for Micromanufacturing, will present a ... cell and tissue models." The presentation will ...
(Date:7/21/2014)... Medicine-led study suggests that parents of obese children often ... childhood weight gain or the importance of daily physical ... , The study is published online in the ... , "Parents have a hard time changing their child,s ... Rhee, MD, and an assistant adjunct professor in the ...
(Date:7/21/2014)... resistance, and cheating in science are among the ... and mycology experts in Montreal at the three ... July 27 to August 1, 2014. Some 2,000 ... at the 14th International Congress of Bacteriology and ... and Eukaryotic Microbiology, and the 16th International Congress ...
Breaking Biology News(10 mins):Louisiana Tech University professor presents at International Bioprinting Congress 2Parents rank their obese children as 'very healthy' 2Montreal hosts International Union of Microbiology Societies congresses 2
... -- 23andMe has launched a project funded by the ... validating 23andMe,s highly-scalable platform for pharmacogenomics research. The company ... and Reinvestment Act of 2009 for "Web-based Phenotyping for ... Human Genome Research Institute. "One of ...
... in the brain called the perirhinal cortex is critical for ... for Mind and Brain have found. The perirhinal cortex ... "declarative" or conscious memories, but the new results show that ... a graduate student at UC Davis. The results were ...
... Is red seaweed a viable future biofuel? Now that ... of yeast that can make short work of fermenting galactose, ... about biofuel crops, they think of corn, miscanthus, and switchgrass. ... choice is marine biomass," said Yong-Su Jin, a U of ...
Cached Biology News:23andMe receives NIH funding to evaluate web-based research on the genetics of drug response 2Where unconscious memories form 2Seaweed as biofuel? Metabolic engineering makes it a viable option 2
Phospho-Cyclin D1 (Thr286) Antibody...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Biology Products: